Cisplatin half-life
WebSep 18, 2024 · Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. ... Its initial half-life is approximately 20 to 30 minutes, with a terminal half-life of 24 hours. ALbumin-bound platinum undergoes slow administration of minimally five days. WebSep 27, 2024 · Nausea and Vomiting: cisplatin for injection can cause severe nausea and vomiting. Use highly effective antiemetic premedication [see Dosage and Administration ( 2.1) and Warnings and Precautions ( 5.3 )]. • Myelosuppression: cisplatin for injection can cause severe myelosuppression with fatalities due to infections.
Cisplatin half-life
Did you know?
WebPlasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus administrations of 50 or 100 mg/m 2 … WebSep 6, 2024 · Plasma concentrations of the parent compound, cisplatin, decay monoexponentially with a half-life of about 20 to 30 minutes following bolus …
WebCisplatin was administered to seven patients with advanced cancer in divided doses of 40 mg/m2 body surface daily for 5 consecutive days. The pharmacokinetics of total Pt was studied on the days 1, 3 and 5 of infusion. ... However, on day 5 of treatment patients showed increased alpha-half life and AUC of plasma Pt, as well as decreased Pt ... WebIn addition, the plasma elimination half-life of cisplatin is prolonged in renal failure. Caution should be exercised in patients with pre-existing renal dysfunction. Cisplatin is contraindicated in patients with serum creatinine levels greater than 0.2 mmol/L. Repeat courses are not advised until serum creatinine is below 0.14 mmol/L and/or ...
WebNov 2, 2024 · Platinum-based chemotherapy can be effective in treating many different types of cancer. For example, cisplatin is one of the most effective drugs for ovarian cancer with as many as 80% of people ... Web1152 rows · Jun 13, 2005 · Cisplatin has a plasma half-life of 30 minutes. The …
WebDec 1, 1987 · Calculated pharmacokinetic parameters (peak concentrations, half-lives, areas under the curve) were compared with the corresponding values in patients at the …
WebCisplatin was found to bind to bovine erythrocyte-SOD at His19 with high selectivity as no other binding sites were identified. 83 Surprisingly, amine ligands as opposed to the chlorido ligand underwent ligand exchange reactions with His19 of SOD. hide a hose complete kitWebOct 5, 2014 · Cisplatin derivatives are used as the mainline treatment of ovarian cancer, despite their severe side effects and development of resistance. Cisplatin is used in … hideahorse folding sawhorsesWebA We can calculate the half-life of the reaction using Equation 14.28: Thus it takes almost 8 h for half of the cisplatin to hydrolyze. B After 5 half-lives (about 38 h), the remaining concentration of cisplatin will be as follows: After 10 half-lives (77 h), the remaining concentration of cisplatin will be as follows: hide a hose vacuum system review on carpetsWebalbumin and the platinum from cisplatin do not dissociate to a significant extent and are slowly eliminated with a minimum half-life of five days or more. Following cisplatin doses of 20 to 120 mg/m2, the concentrations of platinum are highest in liver, prostate, and kidney; somewhat lower in bladder, muscle, hide a hook truckWebSep 7, 2024 · A We can calculate the half-life of the reaction using Equation 14.5.3: t 1 / 2 = 0.693 k = 0.693 1.5 × 10 − 3 m i n − 1 = 4.6 × 10 2 m i n Thus it takes almost 8 h for half of the cisplatin to hydrolyze. B After 5 half-lives (about 38 h), the remaining concentration of cisplatin will be as follows: 0.053 M 2 5 = 0.053 M 32 = 0.0017 M hide a hose installation videoWebUse in Cancer. Cisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with … hide a hickeyWebFeb 28, 2024 · One of the main problems in chemotherapy using platinum drugs as anticancer agents is the resistance phenomenon. Synthesizing and evaluating valid alternative compounds is challenging. This review focuses on the last two years of progress in the studies of platinum (II)- and platinum (IV)-based anticancer complexes. In … hide a hose kit